Quarterly ResultAug 5, 2026, 04:20 PM
Akebia Q2 Net Loss $(8.9)M; Revenue Down to $49.1M
AI Summary
Akebia Therapeutics reported a net loss of $(8.9) million for the second quarter of 2026, a significant decline from a net income of $0.2 million in the same period last year. Total revenues also decreased to $49.1 million from $62.5 million year-over-year. The company continues to incur losses and anticipates needing additional financing, citing the impact of generic competition for Auryxia and potential challenges with Vafseo revenue projections.
Key Highlights
- Net loss for Q2 2026 was $(8.9) million, compared to net income of $0.2 million in Q2 2025.
- Total revenues for Q2 2026 decreased to $49.1 million from $62.5 million in Q2 2025.
- Net loss for H1 2026 was $(18.0) million, compared to net income of $6.4 million in H1 2025.
- Cash and cash equivalents were $155.5 million as of June 30, 2026, down from $184.8 million at Dec 31, 2025.
- Product revenue, net, for Q2 2026 was $46.8 million, down from $60.5 million in Q2 2025.
- Shares outstanding as of July 31, 2026 were 277,106,245.
Price Impact
More from AKBA